The commercial launch of ZUSDURI is on-track, generating $15.8 million in net sales in 2025 during its initial launch period. A permanent J Code for ZUSDURI became effective on January 1, 2026, which is expected to streamline reimbursement and support broader patient access. JELMYTO achieved net product sales of $94.0 million in 2025, representing a 7% year-over-year underlying demand sales growth. UroGen refinanced its existing term loan with Pharmakon Advisors, securing an immediate $200 million in non-dilutive capital and an optional $50 million by June 30, 2027, at a fixed interest rate of 8.25%. The Phase 3 UTOPIA trial for UGN-103 demonstrated a 77.8% three-month complete response rate, with an NDA submission planned for the second half of 2026 and potential FDA approval in 2027. Enrollment for the UGN-104 Phase 3 clinical trial is expected to be completed by the end of 2026. Investigational New Drug (IND)-enabling studies for UGN-501 are ongoing, with an IND submission and Phase 1 trial initiation targeted by the end of 2026. Total revenue for the full year ended December 31, 2025, was $109.8 million, a 21% increase from $90.4 million in 2024. The company reported a net loss of $153.5 million, or ($3.19) per basic and diluted share, for 2025, compared to a net loss of $126.9 million, or ($2.96) per share, in 2024. Cash, cash equivalents, and marketable securities totaled $120.5 million as of December 31, 2025. Guidance for full-year 2026 JELMYTO net product sales is set between $97 million and $101 million, implying 3% to 7% year-over-year growth. Full-year 2026 operating expenses are expected to be in the range of $240 million to $250 million, including $20 million to $24 million in non-cash share-based compensation.